Melanotan II: Research Overview, Mechanisms, and Current Evidence
Melanotan II (MT-II) is a synthetic cyclic peptide that acts as a broad agonist at melanocortin receptors, a property that has made it a subject of pigmentation research. It is unlicensed and its sale is illegal in the United Kingdom and many other countries, and published case reports have linked unregulated use to skin and other adverse effects. The information below summarizes published research for educational and research purposes only. It is not medical advice and is not guidance for use in humans.
Available for research use from our preferred vendor, Project Zero. For laboratory research use only.
How It Works (Preclinical Mechanisms)
In preclinical research, Melanotan II has been reported to act as a non-selective agonist across the melanocortin receptor family, which underlies both its pigmentation effects and its broad side-effect profile.
- Activates melanocortin receptors, including MC1R, stimulating melanocytes to produce eumelanin pigment.
- Also acts on other melanocortin receptors such as MC3R and MC4R, which are linked to appetite and sexual function.
- Reported to stimulate the development of new pigmented and dysplastic moles in case studies.
- Its broad receptor activity is associated with sympathomimetic and other systemic effects reported after self-administration.
Areas of Research Interest
Published literature on Melanotan II is dominated by safety reports and reviews rather than efficacy trials. The contexts below reflect where it appears in the indexed literature.
Pigmentation biology
Studied as a melanocortin agonist that stimulates melanin production, the basis for its unregulated use as a tanning agent.
Documented safety concerns
Reported in case studies to be associated with new and atypical moles, and in some reports with melanoma.
Acute toxicity
Linked in emergency case reports to sympathomimetic symptoms following self-injection.
Regulatory and public-health reviews
Examined in dermatology reviews that contrast unregulated melanotan use with the approved analog afamelanotide.
Reported Study Parameters
For laboratory research use only. The table below reports what the indexed literature describes, with sources. It describes administration and outcomes recorded in case reports and reviews and is not a protocol, recommendation, or guidance for use in humans or animals. Doses in unregulated use are not standardized, which is itself a documented safety concern.
| Research Model | Dose and Route Reported | Source |
|---|---|---|
| Unregulated human use (acute toxicity case report) | Subcutaneous self-injection for tanning; followed by sympathomimetic symptoms requiring hospital treatment; dose not standardized | Eijmael 2022 |
| Unregulated human use (skin case report) | Nasal spray for tanning; associated with oral mucosal melanoma in a 22-year-old; dose not standardized | Yassin Alsabbagh 2025·DOI |
| Human research (regulatory status) | Melanotan II is unlicensed and illegal to sell in many countries; only the related analog afamelanotide is approved, for limited medical indications | Habbema 2017·DOI |
Products are supplied as lyophilized powder requiring reconstitution. For reconstitution concentration math, use the Peptide Calculator.
Latest Research (2013 to 2025)
Peer-reviewed literature indexed on PubMed is dominated by safety case reports and reviews that document the risks of unregulated Melanotan II use.
Oral mucosal melanoma case report
A 2025 case report described a 22-year-old who developed an oral mucosal malignant melanoma after using a Melanotan II nasal spray for tanning, and reviewed the possible association between melanotan use and melanoma. PubMed·DOI
Acute toxicity case report
A 2022 case report described a 27-year-old who presented to the emergency department with sympathomimetic symptoms two hours after subcutaneous self-administration of Melanotan II, underscoring that self-injection is not without risk. PubMed
Review of unregulated use
A 2017 dermatology review summarized the risks of unregulated melanotan I and II, including melanocytic changes in moles and new dysplastic nevi, and contrasted these with the tested, approved analog afamelanotide. PubMed·DOI
Atypical moles after injection
A 2013 case report described a patient who developed multiple new atypical moles within one week of receiving two Melanotan injections, highlighting the peptide's potential to stimulate dysplastic nevi. PubMed
Research Questions
What is Melanotan II?
Melanotan II is a synthetic cyclic peptide that broadly activates melanocortin receptors, stimulating melanin production. It is distinct from the tested and approved analog afamelanotide.
What does the safety literature say?
Case reports have linked unregulated Melanotan II use to new and atypical moles, melanoma in some cases, and acute sympathomimetic symptoms after injection. National health bodies have issued safety warnings.
Is Melanotan II approved or legal?
Melanotan II is unlicensed and its sale is illegal in the United Kingdom and many other countries. Only the related analog afamelanotide is approved, for a small number of specific medical indications.
Referenced Citations
Literature indexed on PubMed.
- Yassin Alsabbagh, A., et al. (2025). Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? Int. J. Oral Maxillofac. Surg., 54(9), 806-808. PubMed·DOI
- Eijmael, M.J.P.M., et al. (2022). The risks of tanning with the Barbie drug. Ned. Tijdschr. Geneeskd., 166. PubMed
- Habbema, L., et al. (2017). Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int. J. Dermatol., 56(10), 975-980. PubMed·DOI
- Reid, C., et al. (2013). Atypical melanocytic naevi following melanotan injection. Ir. Med. J., 106(5), 148-149. PubMed
PeptideInfo.org provides information strictly for educational and research purposes. All referenced products are intended for laboratory and research use only and are not approved for human consumption, medical use, or self-administration. Nothing on this page constitutes medical advice. Research summaries reference literature indexed on PubMed.